Klotho Neurosciences Plans Acquisition of Turn Biotechnologies Assets to Advance Longevity Therapeutics

October 1, 2025- Klotho Neurosciences, a biogenetics company focused on longevity, has announced plans to acquire core assets from Turn Biotechnologies, signaling a significant move to accelerate its development of regenerative and anti-aging therapies.

Klotho has signed a Letter of Intent (LOI) to acquire Turn’s key technologies: the Epigenetic Reprogramming of Age (ERA) platform and the proprietary eTurna RNA delivery system. Turn Biotechnologies specializes in induced pluripotent stem cells (iPSCs) and cellular reprogramming.

The cash and stock deal is contingent upon the completion of due diligence, execution of a definitive agreement, and fulfillment of typical closing conditions.

Acquisition of Core Reprogramming and Delivery Technology

The ERA platform, which was developed at Stanford University and exclusively licensed by the institution, utilizes the eTurna RNA lipid nanoparticle (LNP) delivery system to facilitate cellular rejuvenation. This technology is designed to restore the function of tissues and rejuvenate somatic cells, opening pathways for regenerative therapies across multiple fields, including: Ophthalmology, Dermatology, Osteoarthritis, Muscle health, Immunology, Amyotrophic Lateral Sclerosis (ALS).

A key component of the transaction is Klotho’s acquisition of an existing out-licensing and joint development partnership with a South Korean pharmaceutical company, a collaboration that could be valued at up to $300 million.

Klotho Neurosciences CEO Dr. Joseph Sinkule stated that the acquisition dramatically expands the company’s capabilities. “The Klotho gene is often referred to as the ‘anti-aging gene’. By adding Turn’s ERA technology—which leverages six RNA molecules, including four of the Yamanaka transcription factors that can reset cellular age—together with the eTurna RNA LNP delivery platform, we are expanding beyond a single Klotho gene into a powerful system of cellular rejuvenation.”

Following the anticipated completion of the acquisition, Klotho plans to undergo a rebranding to better represent its broadened mission and therapeutic capabilities. The company also intends to welcome key management and research and development personnel from Turn Biotechnologies.